F S&P 500
5,243.00 -3.25 (-0.06%) F Dow Jones
39,629.00 -13.00 (-0.03%) F Nasdaq
18,246.50 -8.50 (-0.05%) E-mini Russell 2000 Index Futur
2,067.00 -0.90 (-0.04%) Petróleo
78.03 -0.23 (-0.29%) Oro
2,367.50 -7.50 (-0.32%)
Dermisonics, Inc. (DMSI)
Dermisonics, Inc.
2 Park Plaza
Suite 450
Irvine, CA 92614
United States
949-733-1101
Sector(es):
Industria:
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Bruce H. Haglund | Executive Chairman, Acting Principal Exec.,Financial & Accounting Officer | N/D | N/D | 1952 |
Descripción
Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company was formerly known as Second Stage Ventures, Inc. and changed its name to Dermisonics, Inc. in October 2004. Dermisonics, Inc. was founded in 2000 and is based in Irvine, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Dermisonics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
